Key result
Antihypertensive treatments evaluated for death and graft loss in kidney transplant recipients.
Why the study?
The comparative effects of specific blood pressure-lowering treatments on patient-important outcomes following kidney transplantation remained uncertain.
Does antihypertensive treatment reduce all-cause death and graft loss, and improve kidney function in kidney transplant recipients?
Systematic Review
Does antihypertensive treatment reduce all-cause death and graft loss, and improve kidney function in kidney transplant recipients?
In kidney transplant recipients, calcium channel blockers probably reduce death and graft loss, and ARBs may reduce graft loss compared to placebo or standard care.
Answers are grounded in this paper and cite their sources.
CCBs merit first-line use to reduce death and graft loss in kidney recipients; extends limited RCT evidence while leaving ARB/ACEI effects uncertain.
BACKGROUND: The comparative effects of specific blood pressure (BP) lowering treatments on patient-important outcomes following kidney transplantation are uncertain. Our 2009 Cochrane review found that calcium channel blockers (CCBs) improved graft function and prevented graft loss, while the evidence for other BP-lowering treatments was limited. This is an update of the 2009 Cochrane review. OBJECTIVES: To compare the benefits and harms of different classes and combinations of antihypertensive drugs in kidney transplant recipients. SEARCH METHODS: We contacted the Information Specialist and searched the Cochrane Kidney and Transplant Register of Studies up to 3 July 2024 using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs evaluating any BP-lowering agent in recipients of a functioning kidney transplant for at least two weeks were eligible. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the risks of bias and extracted data. Treatment estimates were summarised using the random-effects model and expressed as relative risk (RR) or mean difference (MD) with 95% confidence intervals (CI). Evidence certainty was assessed using Grades of Recommendation, Assessment, Development and Evaluation (GRADE) processes. The primary outcomes included all-cause death, graft loss, and kidney function. MAIN RESULTS: = 47%; moderate certainty evidence), but has uncertain effects on proteinuria. The effects of CCBs, ACEi or ARB compared to placebo or standard care alone on cardiovascular outcomes (including fatal or nonfatal myocardial infarction, fatal or nonfatal stroke) or other adverse events were uncertain. The comparative effects of ACEi plus ARB dual therapy, alpha-blockers, and mineralocorticoid receptor antagonists compared to placebo or standard care alone were rarely evaluated. Head-to-head comparisons of ACEi, ARB or thiazide versus CCB, ACEi versus ARB, CCB or ACEi versus alpha- or beta-blockers, or ACEi plus CCB dual therapy versus ACEi or CCB monotherapy were scarce. No studies reported outcome data for cancer or life participation. AUTHORS' CONCLUSIONS: For kidney transplant recipients, the use of CCB therapy to reduce BP probably reduces death and graft loss compared to placebo or standard care alone, while ARB may reduce graft loss. The effects of ACEi and ARB compared to placebo or standard care on other patient-centred outcomes were uncertain. The effects of dual therapy, alpha-blockers, and mineralocorticoid receptor antagonists compared to placebo or standard care alone and the comparative effects of different treatments were uncertain.
No takes yet. Share an insight, caveat, or question.
Natale et al. (2024) conducted a systematic review in Kidney transplant recipients. Antihypertensive treatment (e.g., CCB, ACEi, ARB) vs. Placebo, standard care, or other antihypertensive agents was evaluated on All-cause death and graft loss. This systematic review evaluated the effects of various antihypertensive treatments on all-cause death, graft loss, and other clinical outcomes in kidney transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: